Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131397 | 0.76 | ALDH1A1 (0.44) | LMNAL3MBTL1ALDH1A1GAA | |
| SCHEMBL2357769 | 0.71 | L3MBTL1 (0.53) | LMNAL3MBTL1ALDH1A1NPSR1GAA | |
| SCHEMBL1521688 | 0.68 | APLNR (0.31) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL225083 | 0.68 | PTGS1 (0.30) | — | |
| SCHEMBL115447 | 0.66 | CYP3A4 (0.33) | — | |
| SCHEMBL715300 | 0.66 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1GAA | |
| SCHEMBL11770176 | 0.66 | HTR2B (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL3150476 | 0.66 | MAPT (0.46) | ALDH1A1 | |
| SCHEMBL1521695 | 0.66 | CYP2A6 (0.44) | — | |
| SCHEMBL3145216 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | claimed |
| EP-1383768-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-09-06 | — | — | EP | claimed |
| EP-1511748-B1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-08-09 | — | — | EP | claimed |
| US-20060148809-A1 | Pyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-07-06 | — | — | US | claimed |
| US-7030128-B2 | Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction | MERCK SHARP & DOHME LTD. (GB) | 2006-04-18 | — | — | US | claimed |
| US-20060058303-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-03-16 | — | — | US | claimed |
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-03-09 | — | — | US | claimed |
| EP-1532136-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | claimed |
| EP-1511748-A1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | claimed |
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-05-13 | — | — | US | claimed |
| WO-2004014891-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| EP-1383768-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-28 | — | — | EP | claimed |
| WO-2003099817-A1 | 8-FLUORIMIDAZO`1,2-A!PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| WO-2003093273-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | claimed |
| WO-2003086406-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-23 | — | — | WO | claimed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | claimed |
| US-7381725-B2 | Pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | disclosed |
| WO-2003086406-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148809-A1 | Pyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA2 | LMNA 3090/4885L3MBTL1 1762/4885ALDH1A1 1059/4885 |
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA4 | LMNA 4507/4885L3MBTL1 864/4885ALDH1A1 495/4885 |
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | LMNA 3625/4885L3MBTL1 1685/4885ALDH1A1 676/4885 |
| US-20060058303-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA2 | LMNA 4083/4885L3MBTL1 1218/4885ALDH1A1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.